About Innocoll
Innocoll is a company based in Philadelphia (United States) founded in 1985 was acquired by Gurnet Point Capital in April 2017. Innocoll has raised $52.85 million across 15 funding rounds from investors including Morgan Stanley, Oaktree Capital Management and Newsmith. The company has 1 employees as of April 08, 2024.
- Headquarter Philadelphia, United States
- Employees 1 as on 08 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Mandvi, Maharashtra, India
-
Annual Revenue
Not available
-
Net Profit
-$584.36 (USD)0as on Mar 31, 2022
-
EBITDA
-$402.89 (USD)0as on Mar 31, 2022
-
Total Equity Funding
$52.85 M (USD)
in 15 rounds
-
Latest Funding Round
$125 M (USD), Debt – Conventional
Jan 28, 2022
-
Investors
Morgan Stanley
& 4 more
-
Employee Count
1
as on Apr 08, 2024
-
Acquired by
Gurnet Point Capital
(Apr 04, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Innocoll
Unlock access to complete
Unlock access to complete
Funding Insights of Innocoll
Innocoll has successfully raised a total of $52.85M across 15 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $125 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Innocoll
Innocoll has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Morgan Stanley, Oaktree Capital Management and Newsmith.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Real estate fund, infrastructure fund, and private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Investment partnerships are built and principal investments are made by B-FLEXION.
|
Locked | Locked | Locked |
Investor details for Innocoll
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Innocoll
Investment portfolio details for Innocoll
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Innocoll
Detailed financials for Innocoll
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Innocoll Comparisons
Peer comparison for Innocoll
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Innocoll
Detailed competitors of Innocoll
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Innocoll
Complete news archive for Innocoll
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innocoll
Innocoll was founded in 1985 and raised its 1st funding round 22 years after it was founded.
Innocoll is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Anthony Zook is the current CEO of Innocoll.
Innocoll is a funded company, having raised a total of $52.85M across 15 funding rounds to date.
As of Apr 08, 2024, the latest employee count at Innocoll is 1.
Innocoll was founded in 1985 in Philadelphia, United States, and operates within the specialty pharmaceutical sector. Collagen-matrix technologies, including COLLAR X and COLLAFILM, are utilized for controlled drug release implants. The product XARACOLL, combining bupivacaine with a collagen matrix, has undergone phase III clinical trials for postsurgical analgesia in hernia repair patients as part of multi-modal therapy.
Innocoll has 5 investors. Key investors include Morgan Stanley, Oaktree Capital Management, Newsmith, Sofinnova, and B-FLEXION.